Loading…
Loading…
See exactly how IHE's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for IHE and 80,000+ other tickers.
The iShares U.S. Pharmaceuticals ETF is designed to replicate the investment performance of a benchmark index. This index consists solely of equity securities from pharmaceutical companies operating within the United States.
The iShares U.S. Pharmaceuticals ETF (IHE) was launched on May 1, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market.
iShares U.S. Pharmaceuticals ETF offers concentrated exposure to US pharma, dominated by Johnson and Johnson (22.5%) and Eli Lilly and Company (20.5%). IHE benefits from structural growth in obesity therapies, robust drug pipelines, and demographic tailwinds but faces high concentration risk. Short-term catalysts include LLY's earnings momentum, FDA drug approvals, sector M&A activity, and potential interest rate improvements.
I issue a hold rating on the iShares US Pharmaceuticals ETF due to fair valuation and mounting near-term headwinds. IHE's portfolio is highly concentrated, with 43% in JNJ and LLY and top 10 holdings totaling 76%. Technical trends have turned concerning, with a recent breach of trendline support and a possible 10% correction to $97 likely through October.
IHE's concentrated pharma holdings delivered 50% returns over one year, while RSPH's equal-weight healthcare approach generated 29%. Risk profiles differ sharply too.
IHE's concentrated pharma focus delivered 50% gains versus IYH's 27.4%, though the broader healthcare fund offers more diversification and $3.9B in assets.